Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: Implications for intervention

Schizophrenia Bulletin

Volumn 41, Issue 3, 2015, Pages 584-596

  Drake, Richard J ^a,b   Nordentoft, Merete ^c   Haddock, Gillian ^b,d   Arango, Celso ^e   Fleischhacker, W Wolfgang ^f   Glenthøj, Birte ^c   Leboyer, Marion ^g   Leucht, Stefan ^h   Leweke, Markus ⁱ   McGuire, Phillip ^j   Meyer Lindenberg, Andreas ⁱ   Rujescu, Dan ^k,l   Sommer, Iris E ^m   Kahn, René S ^m   Lewis, Shon W ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g HENRI MONDOR HOSPITAL   (France)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^j KING'S COLLEGE LONDON   (United Kingdom)

^k UNIVERSITY OF MUNICH   (Germany)

^l MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^m UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

Adherence; First episode; Insight; MHealth; Schizophrenia; Self esteem; Web based

Indexed keywords

ARTICLE; ASSESSMENT OF HUMANS; ATTITUDE TO HEALTH; BIRCHWOOD INSIGHT SCALE; CONTROLLED STUDY; DELUSIONAL DISORDER; DSM-IV; FOLLOW UP; HOSPITAL READMISSION; HUMAN; MEDICATION COMPLIANCE; MOTIVATIONAL INTERVIEWING; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSIS; REMISSION; ROSENBERG SELFAND SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SELF ESTEEM; TREATMENT DURATION; ADULT; AWARENESS; LONGITUDINAL STUDY; PHYSIOLOGY; PSYCHOLOGY; PSYCHOTIC DISORDERS; SELF CONCEPT; STATISTICAL MODEL;

ADULT; AWARENESS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LONGITUDINAL STUDIES; MEDICATION ADHERENCE; MODELS, STATISTICAL; PSYCHOTIC DISORDERS; SELF CONCEPT;

EID: 84929414170     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv015     Document Type: Article

References (126)

1. Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-a review of the past decade. Eur Psychiatry. 2012;27:9-18.
2. Beck EM, Cavelti M, Kvrgic S, Kleim B, Vauth R. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. Schizophr Res. 2011;132:42-49.
3. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl. 1998;172:53-59.
4. Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001;178:506-517.
5. Drake RJ, Pickles A, Bentall RP, et al. The evolution of insight, paranoia and depression during early schizophrenia. Psychol Med. 2004;34:285-292.
6. Crumlish N, Whitty P, Kamali M, et al. Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. Acta Psychiatr Scand. 2005;112:449-455.
7. Ayesa-Arriola R, Morinigo JD, David AS, Perez-Iglesias R, Rodriguez-Sanchez JM, Crespo-Facorro B. Lack of insight 3 years after first-episode psychosis: an unchangeable illness trait determined from first presentation? Schizophr Res. 2014;157:271-277.
8. OPTIMISE. http://www.optimisetrial.eu/. Accessed November 28, 2014.
9. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: new Medical Research Council guidance. BMJ. 2008;337:a1655.
10. Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32:724-742.
11. Cassidy CM, Rabinovitch M, Schmitz N, Joober R, Malla A. A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. J Clin Psychopharmacol. 2010;30:64-67.
12. Verdoux H, Lengronne J, Liraud F, et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand. 2000;102:203-210.
13. Mojtabai R, Lavelle J, Gibson PJ, et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr Serv. 2002;53:337-339.
14. Rabinovitch M, Bechard-Evans L, Schmitz N, Joober R, Malla A. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can J Psychiatry. 2009;54:28-35.
15. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106:286-290.
16. Svedberg B, Mesterton A, Cullberg J. First-episode non-affective psychosis in a total urban population: a 5-year follow-up. Soc Psychiatry Psychiatr Epidemiol. 2001;36:332-337.
17. Gearing RE, Mian I, Sholonsky A, et al. Developing a riskmodel of time to first-relapse for children and adolescents with a psychotic disorder. J Nerv Ment Dis. 2009;197:6-14.
18. Perkins DO, Johnson JL, Hamer RM, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006;83:53-63.
19. Gleeson JF, Alvarez-Jimenez M, Cotton SM, Parker AG, Hetrick S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in firstepisode psychosis. Schizophr Res. 2010;119:79-88.
20. Abdel-Baki A, Ouellet-Plamondon C, Malla A. Pharmacotherapy challenges in patients with first-episode psychosis. J Affect Disord. 2012;138(suppl):S3-S14.
21. Alvarez-Jimenez M, Priede A, Hetrick SE, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012;139:116-128.
22. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247.
23. Caseiro O, Perez-Iglesias R, Mata I, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012;46:1099-1105.
24. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063-2071.
25. Boden R, Brandt L, Kieler H, Andersen M, Reutfors J. Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Res. 2011;133:36-41.
26. Crespo-Facorro B, Perez-Iglesias R, Mata I, et al. Longterm (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, openlabel comparison in first-episode nonaffective psychosis. Psychopharmacology (Berl). 2012;219:225-233.
27. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007;68:654-661.
28. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70:913-920.
29. Wunderink L, Sytema S, Nienhuis FJ, Wiersma D. Clinical recovery in first-episode psychosis. Schizophr Bull. 2009;35:362-369.
30. Gaebel W, Riesbeck M, Wolwer W, et al. Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophr Res. 2014;152:478-486.
31. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40:192-213.
32. Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry Suppl. 2009;52:S1-S4.
33. Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. Does longacting injectable risperidone make a difference to the reallife treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res. 2012;134:187-194.
34. Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333:224.
35. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603-609.
36. Emsley R, Chiliza B, Asmal L, Mashile M, Fusar-Poli P. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry. 2013;7:247-254.
37. Iyer S, Banks N, Roy MA, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives. Can J Psychiatry. 2013;58:23S-29S.
38. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63: 892-909.
39. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry. 2002;159:1653-1664.
40. Velligan DI, Diamond PM, Mintz J, et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull. 2008;34:483-493.
41. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(suppl 4):1-46; quiz 47-48.
42. Quach PL, Mors O, Christensen TO, et al. Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder. Early Interv Psychiatry. 2009;3:66-74.
43. Rabinovitch M, Cassidy C, Schmitz N, Joober R, Malla A. The influence of perceived social support on medication adherence in first-episode psychosis. Can J Psychiatry. 2013;58:59-65.
44. Calvo A, Moreno M, Ruiz-Sancho A, et al. Intervention for adolescents with early-onset psychosis and their families: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2014;53:688-696.
45. McGlashan TH, Carpenter WJ. Does attitude toward psychosis relate to outcome? Am J Psychiatry. 1981;138:797-801.
46. Tait L, Birchwood M, Trower P. Predicting engagement with services for psychosis: insight, symptoms and recovery style. Br J Psychiatry. 2003;182:123-128.
47. Thompson KN, McGorry PD, Harrigan SM. Recovery style and outcome in first-episode psychosis. Schizophr Res. 2003;62:31-36.
48. Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Shared decision making and long-term outcome in schizophrenia treatment. J Clin Psychiatry. 2007;68:992-997.
49. Montreuil TC, Cassidy CM, Rabinovitch M, et al. Case manager- and patient-rated alliance as a predictor of medication adherence in first-episode psychosis. J Clin Psychopharmacol. 2012;32:465-469.
50. Hill M, Crumlish N, Whitty P, et al. Nonadherence to medication four years after a first episode of psychosis and associated risk factors. Psychiatr Serv. 2010;61:189-192.
51. Steger KA, Cassidy C, Rabinovitch M, Joober R, Malla A. Impact of symptom resolution on medication adherence in first episode psychosis. Psychiatry Res. 2012;196:45-51.
52. Drake RJ, Dunn G, Tarrier T, Bentall RP, Haddock G, Lewis SW. Insight as a predictor of the outcome of first episode non-affective psychosis. J Clin Psychiatry. 2007;68:81-86.
53. Czobor P, Volavka J, Derks EM, et al. Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial. J Clin Psychopharmacol. 2013;33:258-261.
54. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20:297-310.
55. Petersen L, Thorup A, Oqhlenschlaeger J, et al. Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial. Can J Psychiatry. 2008;53:660-670.
56. Robinson DG, Woerner MG, Alvir JMJ, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57:209-219.
57. Lepage M, Bodnar M, Joober R, Malla A. Is there an association between neurocognitive performance and medication adherence in first episode psychosis? Early Interv Psychiatry. 2010;4:189-195.
58. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexibledose, multicenter study. J Clin Psychiatry. 2008;69:106-113.
59. Lam JWS, Lui SSY, Wang Y, Chan RCK, Cheung EFC. Prospective memory predicts medication management ability and correlates with non-adherence to medications in individuals with clinically stable schizophrenia. Schizophr Res. 2013;147:293-300.
60. Heinrichs RW, Goldberg JO, Miles AA, McDermid Vaz S. Predictors of medication competence in schizophrenia patients. Psychiatry Res. 2008;157:47-52.
61. Twamley EW, Woods SP, Zurhellen CH, et al. Neuropsychological substrates and everyday functioning implications of prospective memory impairment in schizophrenia. Schizophr Res. 2008;106:42-49.
62. Jonsdottir H, Opjordsmoen S, Birkenaes AB, et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2013;127:23-33.
63. Baloush-Kleinman V, Levine SZ, Roe D, Shnitt D, Weizman A, Poyurovsky M. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study. Schizophr Res. 2011;130:176-181.
64. Gaebel W, Riesbeck M, von Wilmsdorff M, et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol. 2010;20:310-316.
65. Fraguas D, Llorente C, Rapado-Castro M, et al. Attitude toward antipsychotic medication as a predictor of antipsychotic treatment discontinuation in first-episode early-onset psychosis. Rev Psiquiatr Salud Ment. 2008;1:10-17.
66. de Haan L, van Amelsvoort T, Dingemans P, Linszen D. Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up. Pharmacopsychiatry. 2007;40:264-268.
67. Barbeito S, Vega P, Ruiz de Azua S, et al. Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study. BMC Psychiatry. 2013;13:326.
68. McEvoy JP, Johnson J, Perkins D, et al. Insight in first-episode psychosis. Psychol Med. 2006;36:1385-1393.
69. Ko NY, Yeh ML, Hsu ST, Chung HH, Yen CF. Investigation of insight formation using narrative analyses of people with schizophrenia in remission. J Nerv Ment Dis. 2006;194:124-127.
70. Moore A, Sellwood W, Stirling J. Compliance and psychological reactance in schizophrenia. Br J Clin Psychol. 2000;39(pt 3):287-295.
71. Rittmannsberger H, Pachinger T, Keppelmuller P, Wancata J. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr Serv. 2004;55:174-179.
72. Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62:717-724.
73. Klingberg S, Schneider S, Wittorf A, Buchkremer G, Wiedemann G. Collaboration in outpatient antipsychotic drug treatment: analysis of potentially influencing factors. Psychiatry Res. 2008;161:225-234.
74. Koren D, Seidman LJ, Poyurovsky M, et al. The neuropsychological basis of insight in first-episode schizophrenia: a pilot metacognitive study. Schizophr Res. 2004;70:195-202.
75. McLeod HJ, Gumley AI, Macbeth A, Schwannauer M, Lysaker PH. Metacognitive functioning predicts positive and negative symptoms over 12 months in first episode psychosis. J Psychiatr Res. 2014;54:109-115.
76. Lysaker PH, Roe D, Yanos PT. Toward understanding the insight paradox: internalized stigma moderates the association between insight and social functioning, hope, and selfesteem among people with schizophrenia spectrum disorders. Schizophr Bull. 2007;33:192-199.
77. Lysaker PH, McCormick BP, Snethen G, et al. Metacognition and social function in schizophrenia: associations of mastery with functional skills competence. Schizophr Res. 2011;131:214-218.
78. Lysaker PH, Vohs J, Hasson-Ohayon I, Kukla M, Wierwille J, Dimaggio G. Depression and insight in schizophrenia: comparisons of levels of deficits in social cognition and metacognition and internalized stigma across three profiles. Schizophr Res. 2013;148:18-23.
79. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183.
80. Parellada M, Fraguas D, Bombin I, et al. Insight correlates in child- and adolescent-onset first episodes of psychosis: results from the CAFEPS study. Psychol Med. 2009;39:1433-1445.
81. Staring AB, Van der Gaag M, Van den Berge M, Duivenvoorden HJ, Mulder CL. Stigma moderates the associations of insight with depressed mood, low self-esteem, and low quality of life in patients with schizophrenia spectrum disorders. Schizophr Res. 2009;115:363-369.
82. Lester H, Marshall M, Jones P, et al. Views of young people in early intervention services for first-episode psychosis in England. Psychiatr Serv. 2011;62:882-887.
83. Evans-Lacko S, Brohan E, Mojtabai R, Thornicroft G. Association between public views of mental illness and selfstigma among individuals with mental illness in 14 European countries. Psychol Med. 2012;42:1741-1752.
84. Corrigan PW, Rafacz J, Rusch N. Examining a progressive model of self-stigma and its impact on people with serious mental illness. Psychiatry Res. 2011;189:339-343.
85. Tsang HWH, Fung KMT, Chung RCK. Self-stigma and stages of change as predictors of treatment adherence of individuals with schizophrenia. Schizophr Res. 2010;180: 10-15.
86. Jaeger S, Pfiffner C, Weiser P, et al. Adherence styles of schizophrenia patients identified by a latent class analysis of the Medication Adherence Rating Scale (MARS): a six-month follow-up study. Psychiatry Res. 2012;200:83-88.
87. Haley CJ, Drake RJ, Bentall RP, Lewis SW. Health beliefs alter duration of untreated psychosis and attitudes to later treatment in early psychosis. Social Psychiatr Psychiatric Epidemiol. 2002;38:311-316.
88. Pitschel-Walz G, Bauml J, Bender W, Engel RR, Wagner M, Kissling W. Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study. J Clin Psychiatry. 2006;67:443-452.
89. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66:51-57.
90. Olfson M, Uttaro T, Carson WH, Tafesse E. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry. 2005;66:331-338.
91. Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011;71:179-208.
92. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry. 1999;60(suppl 21):25-30.
93. Sibitz I, Unger A, Woppmann A, Zidek T, Amering M. Stigma resistance in patients with schizophrenia. Schizophr Bull. 2011;37:316-323.
94. Cavelti M, Rusch N, Vauth R. Is living with psychosis demoralizing? Insight, self-stigma, and clinical outcome among people with schizophrenia across 1 year. J Nerv Ment Dis. 2014;202:521-529.
95. Shahar G, Davidson L. Depressive symptoms erode selfesteem in severe mental illness: a three-wave, cross-lagged study. J Consult Clin Psychol. 2003;71:890-900.
96. Lewis SW, Tarrier N, Haddock G, et al. A randomised, controlled trial of cognitive-behaviour therapy in acute, early schizophrenia: the SOCRATES trial. Br J Psychiatry. 2002;181(suppl 43):91-98.
97. Tarrier N, Lewis S, Haddock G, et al. Cognitive-behavioural therapy in first-episode and early schizophrenia: 18-month follow-up of a randomised controlled trial. Br J Psychiatry. 2004;184:231-239.
98. Wiffen BD, Rabinowitz J, Lex A, David AS. Correlates, change and 'state or trait' properties of insight in schizophrenia. Schizophr Res. 2010;122:94-103.
99. Tait L, Birchwood M, Trower P. Adapting to the challenge of psychosis: personal resilience and the use of sealing-over (avoidant) coping strategies. Br J Psychiatry. 2004;185:410-415.
100. Amador XF, David AS, eds. Insight in Psychosis. 2nd ed. New York, NY: OUP; 2004.
101. Rosenberg M. Society and the Adolescent Self Image. Princeton, NJ: Princeton University Press; 1965.
102. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand. 1994;89:62-67.
103. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
104. SPSS. SPSS and AMOS 20.0. Chicago, IL: SPSS Inc.; 2009.
105. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.
106. Little RJA, Rubin DB. Statistical Analysis With Missing Data. 2nd ed. New York, NY: John Wiley; 2002.
107. Cavelti M, Kvrgic S, Beck EM, Rusch N, Vauth R. Selfstigma and its relationship with insight, demoralization, and clinical outcome among people with schizophrenia spectrum disorders. Compr Psychiatry. 2012;53:468-479.
108. Heinrichs DW, Cohen BP, Carpenter WT Jr. Early insight and the management of schizophrenic decompensation. J Nerv Ment Dis. 1985;173:133-138.
109. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011.
110. Pijnenborg GH, van Donkersgoed RJ, David AS, Aleman A. Changes in insight during treatment for psychotic disorders: a meta-analysis. Schizophr Res. 2013;144:109-117.
111. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. 2nd ed. New York, NY: The Guilford Press; 2002.
112. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy: 18-month follow-up. Br J Psychiatry. 1998;172:413-419.
113. Gray R, Leese M, Bindman J, et al. Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry. 2006;189:508-514.
114. Schulz M, Gray R, Spiekermann A, Abderhalden C, Behrens J, Driessen M. Adherence therapy following an acute episode of schizophrenia: a multi-centre randomised controlled trial. Schizophr Res. 2013;146:59-63.
115. Brown E, Gray R, Jones M, Whitfield S. Effectiveness of adherence therapy in patients with early psychosis: a mirror image study. Int J Ment Health Nurs. 2013;22:24-34.
116. Staring AB, Van der Gaag M, Koopmans GT, et al. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. Br J Psychiatry. 2010;197:448-455.
117. Reda S, Rowett M, Makhoul S. Prompts to encourage appointment attendance for people with serious mental illness. Cochrane Database Syst Rev. 2001;2:CD002085.
118. Pijnenborg G, Withaar F, Brouwer W, Timmerman M, Bosch R, Evans J. The efficacy of SMS text messages to compensate for the effects of cognitive impairments in schizophrenia. Br J Clin Psychol. 2010;49:259-274.
119. Fjeldsoe BS, Marshall AL, Miller YD. Behavior change interventions delivered by mobile telephone short-message service. Am J Prev Med. 2009;36:165-173.
120. Humphrey Beebe L, Smith K, Bennett C, et al. Cell phone use in people with schizophrenia spectrum disorders. J Psychosoc Nurs. 2010;48:32-37.
121. Spaniel F, Vohlidka P, Hrdlicka J, et al. ITAREPS: information technology aided relapse prevention programme in schizophrenia. Schizophr Res. 2008;98:312-317.
122. Spaniel F, Vohlidka P, Kozeny J, et al. The Information Technology Aided Relapse Prevention Programme in Schizophrenia: an extension of a mirror-design follow-up. Int J Clin Pract. 2008;62:1943-1946.
123. Komatsu H, Sekine Y, Okamura N, et al. Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: a randomized controlled trial. Schizophr Res. 2013;150:240-244.
124. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011;6:CD002831.
125. Valimaki M, Hatonen H, Lahti M, Kuosmanen L, Adams CE. Information and communication technology in patient education and support for people with schizophrenia. Cochrane Database Syst Rev. 2012;10: CD007198.
126. Barrowclough C, Tarrier N, Watts S, Vaughn C, Bamrah JS, Freeman HL. Assessing the functional value of relatives' knowledge about schizophrenia: a preliminary report. Br J Psychiatry. 1987;151:1-8.